Infection is common in neutropenic patients who have hematologic malignancies. Pyomyositis forms abscesses in the skeletal muscle withStaphylococcus aureusas the most common pathogen. Patients with pyomyositis who also have hematologic malignancies are rare especially when the primary diagnosis was the malignancy. In addition, to the authors’ knowledge there are no reports of Pseudomonas species as the myositis pathogen.

The goals of palliative chemotherapy are to improve overall survival and the quality of life through relief of symptoms. On the other hand, chemotherapy has many side effects, such as, myelosupression, neuropathy, gastro-intestinal symptoms, and infertility. On the many known side effects of chemotherapy, bleeding occurs in approximately 6-10% of patients with advanced cancer. Most of bleeding associated with chemotherapy is due to local vessel damage and systemic process, such as, disseminatated intravascular coagulopathy or abnormalities in platelet function or number. This symptom led to worse progression of quality of life and severe stress state in patient and their attendant. Here, the authors report a case of chemotherapy- related bleeding in maxillary cancer patient and successful achievement of hemostasis using interventional endovascular therapy.

Development of two different histologic types of lymphoma in the same person is rare. Sequential lymphoma is defined as two different types of lymphoma occurring sequentially in the same person. In particular, sequential Hodgkin’s lymphoma (HL) following non-Hodgkin’s lymphoma (NHL) is extremely rare. A 63-year-old female diagnosed with B-cell NHL at the mass in T3 received treatment with an R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) protocol for six cycles. However, 12 months later, the patient complained of a left neck mass and excisional biopsy was performed. Microscopically the biopsied tissue showed Reed-Stemberg cells and confirmed the diagnosis of HL. The patient was treated with ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) for four cycles. Although the possibility of a secondary malignancy cannot be excluded, this is a rare case of sequential Hodgkin’s lymphoma following Non-Hodgkin’s lymphoma.